Cystatin C - A fast and reliable biomarker for glomerular filtration rate in head and neck cancer patients

Strahlentherapie und Onkologie

Volumn 187, Issue 3, 2011, Pages 191-201

  Böike, Edwin ^a   Schieren, Gisela ^a   Gripp, Stephan ^a   Steinbach, Gerald ^b   Peiper, Matthias ^a,c   Orth, Klaus ^a   Matuschek, Christiane ^a   Pelzer, Maximilian ^a   Lammering, Guido ^a,d   Houben, Ruud ^d   Antke, Christina ^a   Rump, Lars Christian ^a   Mota, Rodrigo ^a   Gerber, Peter Arne ^a   Schuler, Patrick ^e   Hoffmann, Thomas K ^e   Rusnak, Ethelyn ^f   Hermsen, Derik ^a   Budach, Wilfried ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c Catholic Hospital Essen   (Germany)

^d MAASTRO CLINIC   (Netherlands)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f UNIVERSITY AT BUFFALO   (United States)

Author keywords

Cystatin C; Estimated creatinine clearance; Glomerular filtration rate

Indexed keywords

CISPLATIN; CREATININE; CYSTATIN C; EDETATE CHROMIUM CR 51;

ACCURACY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CORRELATION COEFFICIENT; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GLOMERULUS FILTRATION RATE; GOLD STANDARD; HEAD AND NECK CANCER; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PLASMA CLEARANCE; PROTEIN BLOOD LEVEL; RELIABILITY; SENSITIVITY AND SPECIFICITY; ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADJUVANT CHEMOTHERAPY; BLOOD; COMPARATIVE STUDY; HEAD AND NECK TUMOR; METABOLIC CLEARANCE RATE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTIVE VALUE; REFERENCE VALUE; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, MUCOEPIDERMOID; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CREATININE; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; OTORHINOLARYNGOLOGIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; RENAL INSUFFICIENCY;

EID: 79955668909     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-010-2203-5     Document Type: Article

References (35)

1. Benohr P, Grenz A, Hartmann JT, et al. Cystatin C-a marker for assessment of the glomerular filtration rate in patients with cisplatin chemotherapy. Kidney Blood Press Res 2006;29:32-5. (Pubitemid 43875170)
2. Berger B, Belka C, Weinmann M, et al. Reirradiation with alternating docetaxel-based chemotherapy for recurrent head and neck squamous cell carcinoma: update of a single-center prospective phase II protocol. Strahlenther Onkol 2010;186:255-61.
3. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8:135-60. (Pubitemid 29425900)
4. Bolke E, Gerber PA, Lammering G, et al. Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol 2008;184:105-10. (Pubitemid 351231657)
5. Bolke E, Peiper M, Gripp S. Chemotherapy in unresectable head and neck cancer. N Engl J Med 2008;358:1075; author reply 1075. (Pubitemid 351347114)
6. Brochner-Mortensen J, Rodbro P. Optimum time of blood sampling for determination of glomerular filtration rate by single-injection [51Cr]EDTA plasma clearance. Scand J Clin Lab Invest 1976;36:795-800. (Pubitemid 8062438)
7. Chew JS, Saleem M, Florkowski CM, et al. Cystatin C-a paradigm of evidence based laboratory medicine. Clin Biochem Rev 2008;29:47-62.
8. Chew JS, Saleem M, Florkowski CM, et al. Estimating renal function in oncology patients using cystatin C-based equations. Clin Oncol (R Coll Radiol) 2009;21:425-6.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
10. Driemel O, Ettl T, Kolbl O, et al. Outcome and histopathologic regression in oral squamous cell carcinoma after preoperative radiochemotherapy. Strahlenther Onkol 2009;185:296-302.
11. Ebert E, Werle B, Julke B, et al. Expression of cysteine protease inhibitors stefin A, stefin B, and cystatin C in human lung tumor tissue. Adv Exp Med Biol 1997;421:259-65. (Pubitemid 27432679)
12. Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003;18:2024-31. (Pubitemid 37220307)
13. Kasiske BL, Keane WF. Renal diagnostic testing: past, present and future. Curr Opin Nephrol Hypertens 1996;5:519-20.
14. Kotas M, Schmitt P, Jakob PM, et al. Monitoring of tumor oxygenation changes in head-and-neck carcinoma patients breathing a hyperoxic hypercapnic gas mixture with a noninvasive MRI technique. Strahlenther Onkol 2009;185:19-26.
15. Lah TT, Kokalj-Kunovar M, Drobnic-Kosorok M, et al. Cystatins and cathepsins in breast carcinoma. Biol Chem Hoppe Seyler 1992;373:595-604.
16. Lah TT, Kos J, Blejec A, et al. The Expression of Lysosomal Proteinases and Their Inhibitors in Breast Cancer: Possible Relationship to Prognosis of the Disease. Pathol Oncol Res 1997;3:89-99.
17. Larsson A, Malm J, Grubb A, et al. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest 2004;64:25-30. (Pubitemid 38283206)
18. Le Bricon T, Thervet E, Froissart M, et al. Plasma cystatin C is superior to 24-h creatinine clearance and plasma creatinine for estimation of glomerular filtration rate 3 months after kidney transplantation. Clin Chem 2000;46:1206-7. (Pubitemid 30648770)
19. Leite EA, Giuberti Cdos S, Wainstein AJ, et al. Acute toxicity of long-circulating and pH-sensitive liposomes containing cisplatin in mice after intra-peritoneal administration. Life Sci 2009;84:641-9.
20. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70. (Pubitemid 29135798)
21. Nagy V, Coza O, Ordeanu C, et al. Radiotherapy versus concurrent 5-day cis-platin and radiotherapy in locally advanced cervical carcinoma. Long-term results of a phase III randomized trial. Strahlenther Onkol 2009;185:177-83.
22. Park HR, Ju EJ, Jo SK, et al. Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice. BMC Cancer 2009;9:85.
23. Patterson WP, Reams GP. Renal toxicities of chemotherapy. Semin Oncol 1992;19:521-8.
24. Peponi E, Glanzmann C, Kunz G, et al. Simultaneous Integrated boost intensity-modulated radiotherapy (SIB-IMRT) in nasopharyngeal cancer. Strahlenther Onkol 2010;186:135-42.
25. Platteaux N, Dirix P, Hermans R, et al. Brachial plexopathy after chemora-diotherapy for head and neck squamous cell carcinoma. Strahlenther Onkol 2010;186:517-20.
26. Rutkowski T, Wygoda A, Hutnik M, et al. Intraoperative radiotherapy (IORT) with low-energy photons as a boost in patients with early-stage oral cancer with the indications for postoperative radiotherapy : treatment feasibility and preliminary results. Strahlenther Onkol 2010;186:496-501.
27. Sakata K, Someya M, Hori M, et al. Hyperfractionated accelerated radiotherapy for T1,2 glottic carcinoma. Consideration of time-dose factors. Strahlenther Onkol 2008;184:364-9.
28. Stabuc B, Vrhovec L, Stabuc-Silih M, et al. Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. Clin Chem 2000;46:193-7. (Pubitemid 30104242)
29. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008;51:395-406. (Pubitemid 351273480)
30. Studer G, Seifert B, Glanzmann C. Prediction of distant metastasis in head neck cancer patients: implications for induction chemotherapy and pretreatment staging? Strahlenther Onkol 2008;184:580-5.
31. Weiss RB. Medical oncology-a new subspecialty. W V Med J 1972;68:293-4.
32. Werle B, Schanzenbacher U, Lah TT, et al. Cystatins in non-small cell lung cancer: tissue levels, localization and relation to prognosis. Oncol Rep 2006;16:647-55.
33. Wolff HA, Bosch J, Jung K, et al. High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer. Strahlenther Onkol 2010;186:262-8.
34. Wright JG, Boddy AV, Highley M, et al. Estimation of glomerular filtration rate in cancer patients. Br J Cancer 2001;84:452-9. (Pubitemid 32215868)
35. Zinkin NT, Grall F, Bhaskar K, et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 2008;14:470-7. (Pubitemid 351226115)